BFEC
ALNY icon

Benjamin F. Edwards & Company’s Alnylam Pharmaceuticals ALNY Stock Holding History

Benjamin F. Edwards & Company’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-300
Closed -$26K – 1685
2018
Q3 		$26K Buy
+300
New +$30.2K ﹤0.01% 1047

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Benjamin F. Edwards & Company's ALNY Position: Q2 2024 in Review

Benjamin F. Edwards & Company reduced its Alnylam Pharmaceuticals (ALNY) stake by 12% in Q2 2024, selling an estimated $7.58K and leaving 356 shares worth $87K. The position accounts for ﹤0.01% of the portfolio, ranked #1145.

Benjamin F. Edwards & Company first reported a position in ALNY in Q4 2016 and has held it in 17 quarters since. The position peaked at $314K in Q4 2022. 523 funds tracked by Wall St. Rank hold ALNY as of Q2 2024.

  • Benjamin F. Edwards & Company held 356 shares of Alnylam Pharmaceuticals worth $87K as of Q2 2024.
  • Benjamin F. Edwards & Company sold 48 Alnylam Pharmaceuticals shares in Q2 2024, an estimated $7.58K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #1145 holding.
  • Benjamin F. Edwards & Company first reported a position in Alnylam Pharmaceuticals in Q4 2016 and has held it in 17 quarters since.
  • Benjamin F. Edwards & Company's Alnylam Pharmaceuticals position peaked at $314K in Q4 2022.
  • 523 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.